Metamizol Auxpharma (Metamizole Sodium Monohydrate)

Metamizole inhibits cyclooxygenase enzymes in a non‑selective manner, decreasing prostaglandin production. Lower prostaglandin levels reduce peripheral sensitisation and central pain signalling, while also resetting the hypothalamic set‑point for temperature, thereby producing analgesic and antipyretic effects.

The specific dose of Metamizol Auxpharma is determined by the prescribing clinician based on the patient’s condition, age, weight and renal function. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Safety data for Metamizole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Metamizol Auxpharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizole offers analgesic and antipyretic effects similar to NSAIDs but with a distinct pyrazolone structure. Unlike many NSAIDs, it has a lower risk of gastrointestinal ulceration but carries a rare risk of agranulocytosis. Compared with opioids, it provides pain relief without the risk of dependence or respiratory depression.

Metamizol Auxpharma should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

Metamizol Auxpharma is supplied for oral use. The tablet or oral formulation is taken by mouth with water, according to the dosage prescribed by the treating physician. Swallow the medication whole; do not crush or chew unless directed.

The most serious adverse reactions include agranulocytosis, severe allergic responses such as anaphylaxis, and other blood dyscrasias. Patients should be monitored for signs of infection, rash, or unexplained bleeding, and the drug should be discontinued immediately if these occur.

Metamizol Auxpharma is contraindicated in individuals with known hypersensitivity to metamizole or other pyrazolones, those with a history of agranulocytosis, and patients receiving concurrent myelosuppressive therapy. Caution is also advised for patients with severe renal impairment.